Fierce Pharma

OCTOBER 4, 2024

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo. In 2022, Enjaymo became the first and only therapy specifically approved by the FDA for treating patients with the uncommon blood disorder cold agglutinin disease.

Medicine 204

Medicine FDA Patients 204

MedCity News

OCTOBER 4, 2024

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion. The post Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M appeared first on MedCity News.

Sales 88

Sales Biopharma Pharma 88

Fierce Pharma

OCTOBER 4, 2024

After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.

Manufacturing 171

Manufacturing 171

MedCity News

OCTOBER 4, 2024

More than three-quarters of healthcare organizations reported paying more than $500,000 in ransom as a result of cyberattacks, according to a new report. The post Most Healthcare Organizations Have Paid $500K or More in Ransom Post-Cyberattack, Report Says appeared first on MedCity News.

Healthcare 80

Healthcare Healthcare 80

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

pharmaphorum

OCTOBER 4, 2024

Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).

Food and Drug Administration 65

Food and Drug Administration FDA Food 65

MedCity News

OCTOBER 4, 2024

It has become standard practice for healthcare organizations to focus on identifying and stopping external threats to the privacy and security of data, but one often overlooked risk may be right inside your offices — snooping employees and malicious insider threats. The post User Activity Monitoring: Real-Time Visibility Within the EHR to Stay Ahead of Insider Threats appeared first on MedCity News.

Healthcare 67

Healthcare Healthcare 67

MedCity News

OCTOBER 4, 2024

As organizations dive further into their datasets and explore how artificial intelligence (AI) and machine learning (ML) can help reveal new insights, one thing must remain at the forefront: data quality. The post Data-Driven Transformation: The Role of Data Quality in Accelerating Healthcare Performance appeared first on MedCity News.

Healthcare 65

Healthcare Healthcare 65

Pharmaceutical Technology

OCTOBER 4, 2024

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.

Pharmaceutical 52

Pharmaceutical 52

MedCity News

OCTOBER 4, 2024

Check out news from Alpha Sophia, Rezilient Health, Rippl, Nym, and Mithradote Bio. The post StartUPDATES: New Developments from Healthcare Startups appeared first on MedCity News.

Healthcare 64

Healthcare Healthcare 64

PharmaVoice

OCTOBER 4, 2024

Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.

72

72

Advertisement

MedCity News

OCTOBER 4, 2024

Walmart’s Cancer Centers of Excellence program historically focused on some of the most prevalent cancers, such as breast, lung, colon, prostate, pancreatic and blood cancer. Now, employees can access the same benefit for a whole host of other cancers, including bone, pituitary, liver, thyroid, central nervous system and gynecological. The post Walmart Expands Centers of Excellence Benefit To Include All Cancers appeared first on MedCity News.

56

56

Pharmaceutical Commerce

OCTOBER 4, 2024

In this video interview with Pharma Commerce Editor Nicholas Saraceno, John Stefankiewicz, VP of Analytics, Cencora, details why these pharmacy deserts have become so widespread.

Pharma 52

Pharma 52

PharmaTech

OCTOBER 4, 2024

Pharmaceutical Technology Europe chats with Klaus Ullherr, senior product manager at Syntegon, about challenges facing companies when trying to comply with Annex 1 and how automated systems can help.

Management 52

Management Pharmaceutical 52

Salesforce

OCTOBER 4, 2024

The healthcare sector is undergoing rapid evolution , driven by shifting patient expectations and cutting-edge technologies. Innovations like genomics, personalized medicine, and digital health tools are transforming the landscape. As organizations embrace more digitized operations, including cloud computing in healthcare, they must also navigate a complex web of regulatory requirements such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the General Data Prote

Patients 52

Patients Healthcare Healthcare Healthcare Provider 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales

Pharmaceutical Commerce

OCTOBER 4, 2024

Headlining our October issue of Pharmaceutical Commerce is a look inside an emerging key component of cold chain transport and management—ensuring the safety and control of novel injectable drugs through to their "last mile.

Transportation 52

Transportation Safety Management Pharmaceutical 52

European Pharmaceutical Review

OCTOBER 4, 2024

A study has reported an approach for optimising metronidazole colonic delivery systems, to increase their potential efficacy when treating diverticulitis. Researchers developed intestinal colon-coated sustained-release matrix metronidazole tablets, using a Quality by Design (QbD) approach. Arévalo-Pérez et al. noted that metronidazole is a synthetic nitroimidazole and has activity against anaerobic bacteria.

Side effects 52

Side effects Pharmaceutical Manufacturing 52

PharmExec

OCTOBER 4, 2024

Approval for Opdivo was based on results from the CheckMate-77T trial, which demonstrated that the combination significantly improved event-free survival and pathologic complete response in adults with resectable non-small cell lung cancer without EGFR or ALK rearrangements.

FDA 52

FDA 52

PharmaTech

OCTOBER 4, 2024

In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews experts about key trends impacting small-molecule APIs and excipients, the importance of supply chain resilience, ways in which advanced manufacturing approaches can prove beneficial, and potential hurdles facing companies seeking to secure their small-molecule API and excipient supply chains.

Manufacturing 52

Manufacturing Pharmaceutical 52

Advertisement

Distribution

PharmExec

OCTOBER 4, 2024

From early-stage funding to commercialization, startups must adapt their strategies and messaging to effectively attract investors, build partnerships, and ultimately succeed.

52

52

Pharmaceutical Technology

OCTOBER 4, 2024

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

52

52

PharmaTech

OCTOBER 4, 2024

When the expansion is completed, Piramal expects manufacturing capacity to be increased by the first quarter of 2027 from 104 product batches per year to more than 240.

Manufacturing 52

Manufacturing 52

Pharmaceutical Technology

OCTOBER 4, 2024

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).

Food and Drug Administration 52

Food and Drug Administration FDA Food 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PharmaTech

OCTOBER 4, 2024

Aaron Cowley, PhD, chief technical officer and co-founder, Captozyme, discussed the advancement in development of microbiome-derived therapeutics at BIO 20204.

Manufacturing 52

Manufacturing 52

Pharmaceutical Technology

OCTOBER 4, 2024

National Resilience’s subsidiary Resilience Government Services has received around $17.5m in funding for expanding critical medicine components manufacturing.

Medicine 52

Medicine Government Manufacturing 52

PharmExec

OCTOBER 4, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

FDA 52

FDA 52

Pharmaceutical Technology

OCTOBER 4, 2024

Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic dystrophy type 1.

FDA 52

FDA Leads 52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

PharmExec

OCTOBER 4, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52

Pharma 52

Pharmaceutical Technology

OCTOBER 4, 2024

It is common for sponsors to switch digital platforms between clinical trial phases, but sponsors can achieve much by using the same one.

52

52

PharmExec

OCTOBER 4, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmaceutical Technology

OCTOBER 4, 2024

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical director.

Medical 52

Medical 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety